EMB-01

Phase 2Small molecule

SShanghai EpimAb Biotherapeutics Co., Ltd.

EMB-01 is one of 74 small molecule programs targeting Metastatic Colorectal Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Colorectal CancerRecruiting

Intestinal CancerRecruiting

Metastatic Colorectal CancerPhase 2

Recruiting

Intestinal CancerPhase 2

Recruiting

Competition

Competitive Landscape

159 competitors in Metastatic Colorectal Cancer

#DrugCompanyPhaseTrials

Camptosar

Pfizer

Phase 3

52 2

Keytruda

Merck & Co.

Phase 3

20 3

Wellcovorin

EEastern Cooperative Oncology Group

Phase 3

63 4

Opdivo

Bristol-Myers Squibb

Phase 3

13 5

Braftovi

Pfizer

Phase 3

12 6

Tecentriq

Roche

Phase 3

10 7

FOLFIRI

Amgen

Phase 3

38 8

Yervoy

Bristol-Myers Squibb

Phase 3

7 9

Bayer Aspirin

Bayer

Phase 3

2 10

Lumakras

Amgen

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Recruiting

Metastatic Colorectal Cancer

NCT07314294

Clinical

Trials by Indication[1]

Metastatic Colorectal Cancer1 trial

Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients

Recruiting·SShanghai EpimAb Biotherapeutics Co., Ltd.·Phase 2·NCT07314294·54 enrolled

Intestinal Cancer1 trial

EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers

Recruiting·SShanghai EpimAb Biotherapeutics Co., Ltd.·Phase 1/2·NCT05176665·152 enrolled

Smoking Cessation1 trial

Efficacy and Safety of Combination EMB-001 as a Potential Smoking Cessation Treatment

Unknown status·RRose Research Center, LLC·Phase 2/3·NCT04868253·25 enrolled

Lung Cancer1 trial

EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer

Unknown status·SShanghai EpimAb Biotherapeutics Co., Ltd.·Phase 1/2·NCT05498389·115 enrolled

Advanced/Metastatic Solid Tumors1 trial

A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors

Unknown status·SShanghai EpimAb Biotherapeutics Co., Ltd.·Phase 1/2·NCT03797391·186 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for EMB-01. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EMB-01 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EMB-01. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai EpimAb Biotherapeutics Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SShanghai EpimAb Biotherapeutics Co., Ltd.

EMB-01

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Metastatic Colorectal Cancer1 trial

Intestinal Cancer1 trial

Smoking Cessation1 trial

Lung Cancer1 trial

Advanced/Metastatic Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News